BioNTech’s Bold Leap: From Vaccine Giant to Cancer Cure Pioneer Amid Financial Strain
BioNTech shifts focus from COVID-19 vaccines to pioneering cancer therapies, leveraging mRNA technology. Despite declining earnings, quarterly profits exceeded market expectations, with €1.08 per share and €1.19 billion in revenue.…